India’s First COVID-19 Vaccine Demonstrates Interim Clinical Efficacy of 81%
by Suman Gupta
-
Data from 25,800 participants, received vaccine or placebo in a 1:1 ratio showed that the vaccine candidate was well tolerated.
-
COVAXIN® demonstrated 81% interim efficacy in preventing COVID-19 in those without prior infection after the second dose.
-
Clinical trial to continue through to final analysis at 130 confirmed cases in order to gather further data and to evaluate the efficacy of COVAXIN in additional secondary study endpoints.